Short Communication|Articles in Press

Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations

Published:February 16, 2023DOI:


      • Many researchers use ‘before and after’ approaches to study lung function recovery around a pulmonary exacerbation.
      • This method lacks comparators and ascribes recovery failure to PEx.
      • Comparisons and simulations show ‘recovery’ is prone to artifact and poorly define PEx contributions to disease progression.


      CF registry pulmonary exacerbation (PEx) analyses have employed “before and after” spirometry recovery, where the best percent predicted forced expiratory volume in 1 s (ppFEV1) prior to PEx (“baseline”) is compared to the best ppFEV1 <3 months post-PEx. This methodology lacks comparators and ascribes recovery failure to PEx.
      Herein, we describe 2014 CF Foundation Patient Registry PEx analyses including a comparator: recovery around nonPEx events, birthdays. 49.6% of 7357 individuals with PEx achieved baseline ppFEV1 recovery while 36.6% of 14,141 achieved baseline recovery after birthdays; individuals with both PEx and birthdays were more likely to recover baseline after PEx than after birthdays (47% versus 34%); mean ppFEV1 declines were 0.3 (SD=9.3) and 3.1 (9.3), respectively. Post-event measure number had more effect on baseline recovery than did real ppFEV1 loss in simulations, suggesting that PEx recovery analyses lacking comparators are prone to artifact and poorly describe PEx contributions to disease progression.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferkol T.
        • Rosenfeld M.
        • Milla C.E.
        Cystic fibrosis pulmonary exacerbations.
        J. Pediatr. 2006; 148: 259-264
        • Goss C.
        • Burns J.
        Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis.
        Thorax. 2007; 62: 360-367
        • Britto M.
        • Kotagal U.
        • Hornung R.
        • Atherton H.
        • Tsevat J.
        • Wilmott R
        Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.
        Chest. 2002; 121: 64-72
        • Liou T.
        • Adler F.
        • Fitzsimmons S.
        • Cahill B.
        • Hibbs J.
        • Marshall B.
        Predictive 5-year survivorship model of cystic fibrosis.
        Am. J. Epidemiol. 2001; 153: 345-352
        • Lieu T.
        • Ray G.
        • Farmer G.
        • Shay G.
        The cost of medical care for patients with cystic fibrosis in a health maintenance organization.
        Pediatrics. 1999; 103: e72
        • Rabin H.R.
        • Butler S.M.
        • Wohl M.E.
        • Geller D.E.
        • Colin A.A.
        • Schidlow D.V.
        • Johnson C.A.
        • Konstan M.W.
        • Regelmann W.E.
        Epidemiologic study of cystic fibrosis. Pulmonary exacerbations in cystic fibrosis.
        Pediatr. Pulmonol. 2004; 37 (May): 400-406
        • Cystic Fibrosis Foundation
        Treatment of Pulmonary Exacerbation of Cystic Fibrosis. Clinical Practice Guidelines for Cystic Fibrosis.
        Cystic Fibrosis Foundation, Bethesda, MD1997
        • Flume P.A.
        • Mogayzel Jr, P.J.
        • Robinson K.A.
        • Goss C.H.
        • Rosenblatt R.L.
        • Kuhn R.J.
        • Marshall B.C.
        Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
        Am. J. Respir. Crit. Care Med. 2009; 180 (Nov 1): 802-808
        • Wagener J.S.
        • VanDevanter D.R.
        • Konstan M.W.
        • Pasta D.J.
        • Millar S.J.
        • Morgan W.J.
        Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
        Pediatr. Pulmonol. 2020; 55: 828-834
        • Sanders D.B.
        • Zhao Q.
        • Li Z.
        • Farrell P.M
        Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
        Pediatr. Pulmonol. 2017; 52: 1268-1275
        • Collaco J.M.
        • Green D.M.
        • Cutting G.R.
        • Naughton K.M.
        • Mogayzel Jr., P.J.
        Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.
        Am. J. Respir. Crit. Care Med. 2010; 182 (Nov 1): 1137-1143
        • Sanders D.
        • Bittner R.
        • Rosenfeld M.
        • Hoffman L.
        • Redding G.
        • Goss C.
        Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
        Am. J. Respir. Crit. Care Med. 2010; 182: 627-632
        • Waters V.J.
        • Stanojevic S.
        • Sonneveld N.
        • Klingel M.
        • Grasemann H.
        • Yau Y.C.
        • et al.
        Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.
        J. Cyst. Fibros. 2015; 14: 755-762
        • Knapp E.A.
        • Fink A.K.
        • Goss C.H.
        • Sewall A.
        • Ostrenga J.
        • Dowd C.
        • et al.
        The cystic fibrosis foundation patient registry: design and methods of a national observational disease registry.
        Ann. Am. Thorac. Soc. 2016; 13: 1173-1179
        • Quanjer P.H.
        • Stanojevic S.
        • Cole T.J.
        • Baur X.
        • Hall G.L.
        • Culver B.H.
        • et al.
        Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.
        Eur. Respir. J. 2012; 40: 1324-1343
        • Ramsey B.W.
        • Pepe M.S.
        • Quan J.M.
        • Otto K.L.
        • Montgomery A.B.
        • Williams-Warren J.
        • Vasiljev-K M.
        • Borowitz D.
        • Bowman C.M.
        • Marshall B.C.
        • Marshall S.
        • Smith A.L
        Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
        N. Engl. J. Med. 1999; 340 (Jan 7): 23-30
        • Retsch-Bogart G.Z.
        • Quittner A.L.
        • Gibson R.L.
        • Oermann C.M.
        • McCoy K.S.
        • Montgomery A.B.
        • Cooper P.J.
        Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
        Chest. 2009; 135: 1223-1232
        • Moskowitz S.M.
        • Emerson J.C.
        • McNamara S.
        • Shell R.D.
        • Orenstein D.M.
        • Rosenbluth D.
        • Katz M.F.
        • Ahrens R.
        • Hornick D.
        • Joseph P.M.
        • Gibson R.L.
        • Aitken M.L.
        • Benton W.W.
        • Burns J.L.
        Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
        Pediatr. Pulmonol. 2011; 46 (Feb): 184-192
        • VanDevanter D.R.
        • Heltshe S.L.
        • Spahr J.
        • Beckett V.V.
        • Daines C.L.
        • Dasenbrook E.C.
        • Gibson R.L.
        • Raksha J.
        • Sanders D.B.
        • Goss C.H.
        • Flume P.A.
        • STOP Study Group
        Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.
        J. Cyst. Fibros. 2017; 16 (Sep): 607-615